The European Patent Office intends to grant Idogen’s patent application

Idogen AB (”Idogen”) today announces that the European Patent Office (”EPO”) has issued a “Notice of Intention to Grant”, which means that the patent office intends to grant Idogen’s patent application, covering the company’s tolerogenic vaccine technology. A related patent application received a Notice of Allowance in Japan in December 2016. The patent, and its validation in key European countries, will provide Idogen’s tolerogenic vaccine technology with broad protection and further strengthens the company’s patent portfolio.

The European Patent Office has communicated its intention to grant Idogen’s Patent Application No. 11850142.8. The patent belongs to Idogen’s second patent family and covers Idogen’s technology for induction of IDO for treatment of autoimmune diseases and transplant rejection. A related application received “Notice of Allowance” in Japan in December 2016 and other applications are pending in Canada, the US and internationally. The granted patent will complement an earlier European Patent in Idogen’s first patent family, granted in December 2013. Final grant of this second patent by the EPO is expected to occur within two to three months following the completion of routine formalities by Idogen during the coming weeks.

CEO Lars Hedbys commented that ”This patent provides very important protection for our tolerogenic vaccine platform on the European market – a key market for us. The decision that the European Patent Office intends to grant the patent is very pleasing”.

For additional information about Idogen, please contact:

Lars Hedbys, CEO

Tel: +46 (0)46-275 63 30

E-mail: lars.hedbys@idogen.com

This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 13th of January 2017.

Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement.
The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com